New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.

Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for investors in the Danish pharmaceutical giant. And both UBS and Citi are highlighting the pill's trajectory as the defining question for the company's medium-term

Novo Nordisk's 50% Wegovy price cut, aims to secure market share and expand the addressable market. Find out why NVO stock is still a buy.

Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.

BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to discuss the battle for GLP-1 dominance between Novo Nordisk (NVO) and Eli Lilly (LLY).

Novo Nordisk ( NVO) is more active scouting for deals than ever before, its CEO Mike Doustdar told CNBC in an interview following its earnings report.

Healthcare stocks have struggled in 2026. With a year-to-date (YTD) loss of about 6%, that corner of the market has been the worst performer among all 11 sectors of the S&P 500 in 2026. While that has been reflected in the YTD losses of some of Big Pharma's biggest names,

Novo Nordisk has had a difficult year, faced with intense competition in the obesity space; however, the company’s Wegovy pill is offering a route to greener financial pastures.